Every 8-K that Rockwell Medical, Inc. (DE) (RMTI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RMTI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RMTI filings page.
Rockwell Medical, Inc. furnished an updated corporate presentation as a Regulation FD Disclosure. The presentation, dated August 13, 2026, is provided as Exhibit 99.1 and is incorporated by reference. The materials are furnished, not filed, so they are not subject to Section 18 liabilities and are not automatically incorporated into Securities Act or Exchange Act filings.
Rockwell Medical, Inc. reported second quarter 2026 net sales of $17.8 million, up 11% from $16.1 million a year earlier, driven by new customers in the Western U.S. and higher purchasing from existing customers. Gross profit rose to $3.2 million, a 30% increase, and gross margin expanded to 18% from 16% as lower manufacturing costs and higher volume improved profitability.
The company recorded a net loss of $1.2 million for the quarter, improving from a $1.5 million loss a year ago and $1.6 million in the first quarter of 2026. Adjusted EBITDA was a loss of $0.2 million, similar to the prior year period, while operating cash flow turned positive at $2.1 million, lifting cash, cash equivalents and investments to $24.8 million as of June 30, 2026.
For full-year 2026, Rockwell Medical reiterates guidance of $70–$75 million in net sales, gross margin of 18%–22%, Adjusted EBITDA of $1–$2 million, and positive operating cash flow. During the quarter it signed and extended multi-year product purchase agreements with dialysis providers and completed a 1-for-10 reverse stock split, after which it regained compliance with Nasdaq’s minimum bid price requirement.
Rockwell Medical, Inc. reported that it has received notice from Nasdaq that the company has regained compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The shares maintained a closing bid of at least $1.00 from July 1, 2026 through July 15, 2026, and Nasdaq has closed the compliance matter. The company states it is now in full compliance with all Nasdaq continued listing requirements, and its common stock remains listed and traded under the ticker RMTI.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide, focused on supporting patients with end-stage kidney disease.
Rockwell Medical, Inc. is implementing a one-for-ten reverse stock split of its common stock. Effective at 12:01 a.m. Eastern Time on July 1, 2026, each ten existing shares will automatically combine into one new share, with no action required from stockholders.
No fractional shares will be issued; instead, holders will receive cash equal to the applicable fraction multiplied by the June 30, 2026 Nasdaq closing price, adjusted for the split. The common stock will continue trading on Nasdaq under the symbol RMTI and will trade on a split-adjusted basis with a new CUSIP. Proportionate adjustments will also be made to equity awards, preferred stock conversion terms and warrants, while authorized capital and par value remain unchanged.
Rockwell Medical, Inc. reported voting results from its 2026 annual shareholder meeting, where stockholders approved all four proposals, including elections, pay, auditor and capital structure changes.
Two Class II directors, Joseph Dawson and Joan Lau, Ph.D., were elected with 9,812,114 and 9,890,379 votes in favor, respectively. Stockholders endorsed executive compensation on an advisory basis with 8,232,918 votes for and ratified EisnerAmper LLP as auditor with 22,996,530 votes for. They also approved an amendment to the Certificate of Incorporation authorizing a reverse stock split of the common stock, with 16,993,038 votes for and 6,597,036 against.
Rockwell Medical, Inc. reported that Nasdaq notified the company on May 8, 2026 that its common stock no longer meets the Nasdaq Capital Market’s Minimum Bid Price Requirement, which requires a minimum closing bid price of $1.00 per share for 30 consecutive business days.
The notice does not immediately affect trading, and the shares will remain listed while Rockwell has 180 calendar days, until November 4, 2026, to regain compliance by having a closing bid price of at least $1.00 for ten consecutive business days. Rockwell has included a proposal for a reverse stock split in its 2026 proxy statement, which it believes could restore compliance if approved and implemented, though it cautions there is no assurance it will regain or maintain compliance or receive additional relief from Nasdaq.
Rockwell Medical, Inc. furnished an updated corporate presentation, dated May 7, 2026, for investor and public reference. The presentation is provided as Exhibit 99.1 under a current report. The material is furnished under Regulation FD, meaning it is not treated as filed for liability purposes.
Rockwell Medical reported first quarter 2026 results showing mixed top-line but improving profitability metrics. Net sales were $17.3 million, down 8% from $18.9 million a year earlier, mainly due to lower purchasing by one customer. Gross profit was $2.9 million and gross margin improved slightly to 17% from 16%.
The company posted a net loss of $1.6 million, similar to the prior year, while Adjusted EBITDA improved to a loss of $0.3 million from a $0.4 million loss. Cash, cash equivalents and investments were $23.9 million. For 2026, Rockwell guides to net sales of $70–$75 million, gross margin of 18%–22%, Adjusted EBITDA of $1–$2 million, and positive operating cash flow, supported by pricing actions and operational changes expected to add over $3 million in annualized gross profit.
Rockwell Medical, Inc. furnished an updated corporate presentation as part of a current report. The presentation, dated March 26, 2026, is attached as Exhibit 99.1 and provides corporate information under Regulation FD.
The company notes this material is furnished, not filed, so it is not subject to certain Exchange Act liabilities and will only be incorporated into other securities filings if specifically referenced.
Rockwell Medical, Inc. reported fourth quarter and full-year 2025 results showing a sharp revenue decline but improved margins and positive cash generation. Net sales were $18.3 million in Q4 2025 versus $24.7 million a year earlier, and $69.3 million for 2025 compared with $101.5 million in 2024, mainly due to lower purchase volume from one customer.
Q4 2025 gross margin improved to 21% from 15%, with full-year 2025 gross margin steady at 17%. The company posted a 2025 net loss of $5.3 million versus $0.5 million in 2024, but remained profitable on an Adjusted EBITDA basis at $0.3 million. Cash, cash equivalents and investments were $25.0 million at December 31, 2025, up from $21.6 million. For 2026, Rockwell guides to Adjusted EBITDA of $1 million to $2 million and positive operating cash flow.
Rockwell Medical, Inc. submitted a current report describing that it has issued a press release with preliminary, unaudited financial results for the quarter and full year ended December 31, 2025. These figures are based on management’s initial analysis and remain subject to the company’s normal quarter-end and year-end closing procedures, internal review, and audit by its independent registered public accounting firm, so actual results may differ from the preliminary figures in the press release.
The report clarifies that the information under the results section and the attached press release are being furnished, not filed, which affects how they are treated under securities laws. It also highlights that the press release includes forward-looking statements about future financial condition, operating results, revenue growth, profitability, cost reductions, and product diversification, all of which are subject to risks described in Rockwell Medical’s prior SEC filings.
Rockwell Medical, Inc. reported a change in its Board of Directors. On November 17, 2025, Andrea Heslin Smiley resigned from the Board and its committees, and the company stated that her resignation was not due to any disagreement over operations, policies, or practices.
The Board appointed Joseph H. Dawson, aged 60, as a Class II director effective the same day, to serve until the 2026 Annual Meeting of Stockholders. He will also serve on the Nominating and Corporate Governance Committee.
Under the non-employee director compensation policy, Mr. Dawson will receive an annual cash retainer of $45,000 as a director and $5,000 for serving on the committee, pro-rated through the 2026 Annual Meeting. He was granted an option to purchase 25,000 shares of common stock and 25,000 restricted stock units under the Amended and Restated 2018 Long Term Incentive Plan, with both equity awards vesting on November 17, 2026, subject to continued service.
Rockwell Medical, Inc. (RMTI) furnished an updated corporate presentation under Regulation FD. The presentation, dated November 12, 2025, is provided as Exhibit 99.1 to a Form 8‑K.
The company states the information in this report, including Exhibit 99.1, is furnished and not deemed “filed” under the Exchange Act pursuant to General Instruction B.2. The exhibit list also includes Exhibit 104 for the cover page interactive data file.
Rockwell Medical, Inc. (RMTI) furnished its quarterly results press release. The company reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished it as Exhibit 99.1 to a Form 8-K.
Consistent with General Instruction B.2, the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other filings unless expressly stated. The report was signed by Chief Executive Officer Mark Strobeck.
Rockwell Medical, Inc. reported that its Board of Directors appointed Heather Hunter as Senior Vice President and Chief Operating Officer, effective immediately. She has been serving as the company’s Senior Vice President and Chief Corporate Affairs Officer since August 2022 and previously held senior communications and corporate affairs roles at Venatorx Pharmaceuticals, Safeguard Scientifics, and W.P. Carey.
Hunter’s existing employment agreement, dated August 31, 2022 and amended May 20, 2025, provides an annualized base salary of $323,574, a target bonus opportunity equal to 45% of base salary, eligibility for long-term incentive awards, and an initial time-based stock option to purchase up to 60,000 shares vesting over four years. The agreement includes severance and equity-vesting protections in cases of death, disability, certain terminations without cause or for good reason, and change of control, along with standard confidentiality, inventions assignment, non-interference, and non-competition obligations.
Rockwell Medical, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The company explicitly states the information in Item 2.02 and Exhibit 99.1 is being furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act filings except by specific reference. Item 9.01 lists the furnished exhibits: Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File in Inline XBRL). The report is signed on behalf of the registrant by Mark Strobeck, Chief Executive Officer.